Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS Author FAQs
    • COVID-19 submission information
  • Alerts
  • Subscriptions

Snus in pregnancy and infant birth size: a mother–child birth cohort study

Ina Kreyberg, Katarina Hilde, Karen Eline S. Bains, Kai-Håkon Carlsen, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Christine M. Jonassen, Live S. Nordhagen, Björn Nordlund, Corina S. Rueegg, Katrine D. Sjøborg, Håvard O. Skjerven, Anne C. Staff, Riyas Vettukattil, Karin C. Lødrup Carlsen
ERJ Open Research 2019 5: 00255-2019; DOI: 10.1183/23120541.00255-2019
Ina Kreyberg
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: inakreyberg@hotmail.com
Katarina Hilde
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Eline S. Bains
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kai-Håkon Carlsen
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Berit Granum
4Dept of Toxicology and Risk Assessment, Norwegian Institute of Public Health, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guttorm Haugen
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gunilla Hedlin
5Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
6Dept of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine M. Jonassen
7Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway
8Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Live S. Nordhagen
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
9VID Specialized University, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Live S. Nordhagen
Björn Nordlund
5Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden
6Dept of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Björn Nordlund
Corina S. Rueegg
10Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital and University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katrine D. Sjøborg
11Dept of Obstetrics and Gynaecology, Østfold Hospital Trust, Kalnes, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Håvard O. Skjerven
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne C. Staff
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne C. Staff
Riyas Vettukattil
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Riyas Vettukattil
Karin C. Lødrup Carlsen
1Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
2Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
12A full list of PreventADALL study group members and their affiliations can be found in the Acknowledgements section
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Rationale While recent studies show that maternal use of snus during pregnancy is increasing, the potential effects on infant birth size is less investigated, with conflicting results.

Objectives We aimed to determine if maternal use of snus during pregnancy influences the infant anthropometric and proportional size measures at birth.

Methods In 2313 mother–child pairs from the population-based, mother–child birth cohort PreventADALL (Preventing Atopic Dermatitis and ALLergies) in Norway and Sweden, we assessed nicotine exposure by electronic questionnaire(s) at 18 and 34 weeks of pregnancy, and anthropometric measurements at birth. Associations between snus exposure and birth size outcomes were analysed by general linear regression.

Results Birthweight was not significantly different in infants exposed to snus in general, and up to 18 weeks of pregnancy in particular, when adjusting for relevant confounders including maternal age, gestational age at birth, pre-pregnancy body mass index, parity, fetal sex and maternal gestational weight gain up to 18 weeks. We found no significant effect of snus use on the other anthropometric or proportional size measures in multivariable linear regression models. Most women stopped snus use in early pregnancy.

Conclusion Exposure to snus use in early pregnancy, with most women stopping when knowing about their pregnancy, was not associated with birth size. We were unable to conclude on effects of continued snus use during pregnancy because of lack of exposure in our cohort.

Abstract

Snus use in pregnancy, reported by 7.1% of 2313 women, was not associated with infant birth size. As most women stopped snus use by 6 weeks gestational age, it was not possible to assess potential birth size effects of persistent use during pregnancy. http://bit.ly/2IG8Vnk

Introduction

Smoking during pregnancy is well established as one of the most modifiable risk factors for adverse pregnancy and infant related health effects [1], with effects related to infant birth size including increased risk of low birthweight, length and head circumference [2, 3], ponderal index [3] and being small for gestational age (SGA) [4–6]. Nonlinear decrease in mean adjusted birthweight has been observed with increasing number of cigarettes smoked per day during pregnancy [7, 8]. Tobacco exposure may influence fetal growth throughout pregnancy, with small but significant reductions in head size and femur length in the first trimester, reduced growth after the first trimester [9] and selective reduction in abdominal circumference and muscle mass in fetuses exposed in the last trimester [10]. However, it is unclear whether these findings may be extended to smokeless tobacco.

The use of snus, a smokeless tobacco product also known as moist snuff, and other smokeless nicotine products such as electronic cigarettes have increased in recent years [11, 12], paralleling decreased smoking rates among young women in many countries [13]. A similar increased use of snus in women of reproductive age in Norway and Sweden [12, 14] is also shown during pregnancy [14, 15]. We recently showed in the Preventing Atopic Dermatitis and Allergies in Children (PreventADALL) study that 11.3% of pregnant women reported use of any tobacco or nicotine products by 34 weeks of pregnancy; most commonly as snus only in 6.5%, followed by cigarette smoking only in 4.1% and dual smoking and snus in <1%. Most women stopped snus use or cigarette smoking early in pregnancy, usually within pregnancy week six [16]. Nicotine from snus readily crosses the placenta into the fetal compartments and, together with its metabolites such as cotinine, concentrates in fetal blood, urine, meconium and amniotic fluid [17, 18]. Despite substantial documentation in animal models showing adverse effects in the offspring of nicotine exposure by the pregnant female, there are few studies to verify these findings in humans [19, 20]. Exposure to snus during pregnancy increased the risk of preterm birth [21], stillbirth [22, 23], oral cleft malformation [24] and neonatal apnoea [25] in Swedish Medical Birth Register studies, while altered infant heart rate variability was observed in a prospective observational study [26]. While a study from India showed an average of 87 g reduced birthweight (adjusted for gestational age) in infants born to women who used smokeless tobacco regularly in pregnancy [27], no significant effect of snus use was observed on birthweight in the Swedish registry study [28]. Thus, the effect of snus on birthweight is unclear, nor are we aware of studies assessing potential effects of snus use on other infant size measures at birth [19].

Therefore, we aimed to determine if maternal use of snus in pregnancy might affect infant anthropometric and proportional size measures at birth.

Subjects and methods

Study design

This study is based on the large population-based, prospective mother–child birth cohort PreventADALL [29], enrolling 2697 women with 2701 pregnancies and their 2397 infants born at a gestational age of ≥35.0 weeks without serious neonatal disease. The main objectives of the PreventADALL study are to determine whether primary prevention of allergic diseases is possible through a 2×2 factorially designed, randomised trial of two interventions. Additionally, early life exposures and factors involved in allergic diseases and noncommunicable diseases are assessed. Pregnant females were recruited at the routine ultrasound screening at second trimester between gestational weeks 16 and 22, in hospitals from the general, nonselected population from the greater area of Oslo and southeast Norway as well as from the Stockholm area in Sweden between December 2014 and October 2016 [29]. Details of recruitment, inclusion and exclusion criteria are given in the supplementary material.

The present study included all 2313 mother–child pairs with available exposure data of any type of nicotine or tobacco product from electronic questionnaires at 18 and/or 34 weeks of pregnancy and whose included singleton newborn babies had anthropometric measurements performed at birth (supplementary figure S1).

Maternal written consent was obtained upon primary enrolment and signed by both parents at newborn inclusion. The PreventADALL study was approved by the regional committees for medical and health research ethics in South-Eastern Norway (2014/518) and in Sweden (2014/2242-31/4).

Subjects

Baseline characteristics among the included and the excluded study participants were similar, except for marital status, previous smoking history and gestational age at birth as shown in supplementary table S1.

Methods

From electronic questionnaires completed by the women at 18 and 34 weeks of pregnancy, we collected detailed information about snus, cigarette smoking, nicotine replacement therapy (NRT) or electronic cigarettes: never, ever, prior to pregnancy, and during pregnancy up to 18 weeks and from 18 weeks to 34 weeks [16]. Background characteristics and history of previous and present pregnancies were obtained from the 18-week questionnaire and a brief interview at enrolment. Whether the women reported the ultrasound-corrected gestational age or calculated gestational age from their last menstrual period is not known. Study personnel measured maternal weight and height at the 18-week inclusion visit. Pre-pregnancy weight was obtained by self-report rather than by objective measures.

Dedicated trained study personnel using a non-elastic measuring tape performed infant anthropometric measures within the first 24 h after delivery. We report the mean of two left upper arm circumference measures midway between the acromial and olecranon process, and the mean of three thoracic and abdominal circumference measures performed at end-expiration when possible. For the thoracic circumference measures we placed the lower part of the measuring tape in line with the most caudal part of the xyphoid process. For the abdominal circumference measures the lower end of the measuring tape was placed in line with the cranial part of the umbilicus. All values were recorded in centimetres with one decimal, and mean values were calculated and rounded when appropriate. Background for the methods used is described in the supplementary material. Birthweight, length (crown–heel) and head circumference as well as placenta weight was collected from the hospital records. Placenta was weighed and recorded by the midwives within 30 min of delivery according to hospital guidelines.

Outcomes, exposures and covariates

The main outcome was birthweight (in grams). Secondary anthropometric outcomes were birth length, head circumference, thoracic circumference, abdominal circumference and left mid upper arm circumference (all in centimetres), while the ratios of abdominal circumference to head circumference, thoracic circumference to head circumference, thoracic circumference to abdominal circumference and finally birthweight to placenta weight were proportional size outcomes.

The main exposure variables were based on any use of snus and/or smoke in pregnancy categorised into never in pregnancy (“never”), snus alone in pregnancy (“snus only”) and smoking including dual snus users in pregnancy (“smoke/dual”). To differentiate between early and late snus exposure, we also separated the snus only group into “snus only 18 weeks” and “snus only 34 weeks”. Women who reported ever-use of snus and/or smoking before pregnancy were included in the never group representing never-use during pregnancy. As only four women reported using NRT or electronic cigarettes, of whom three stopped when recognising pregnancy, they were included in the analyses based upon their use of snus and cigarette smoking.

Potential covariates were based upon factors previously shown to be associated with snus use in pregnancy [16] including maternal age, marital status, previous smoking history, in utero smoking exposure of the index women and living area. Additionally, we included factors possibly associated with birth size of the baby such as maternal education, pre-pregnancy body mass index (BMI), parity, fetal sex and gestational age at delivery (days). Further, as smoking cessation during pregnancy may cause weight gain [30, 31], we performed sensitivity analyses including adjustment for maternal gestational weight gain from pre-pregnancy to 18 weeks of pregnancy. The gestational age was based on femur length obtained at the routine second trimester ultrasound, as described previously [29].

Statistical analysis

Categorical variables are presented as numbers and percentages, and continuous variables as means with standard deviation or 95% confidence intervals. Differences between categorical variables were analysed by Chi-squared test and numerical data by one-way ANOVA tests.

Associations between snus exposure and birth size outcomes were analysed using univariable and multivariable linear regression models with the birth outcomes as dependent variable and snus use as independent variable. The group of never snus users were defined as the reference group. In the multivariable models we included all covariates that were known potential confounders associated with snus use from our previous study [16] and the literature in general. Significant covariates with a p-value <0.05 were kept in the final models, as appropriate for each outcome, with details given in supplementary table S3. Sensitivity analyses including adjustment for maternal gestational weight gain from pre-pregnancy to 18 weeks of pregnancy were performed in case of significant associations between snus use and the respective birth outcome.

The significance level was set to 5%. Because of low numbers of missing data we performed complete case analysis only. All analyses were performed using SPSS Statistics (version 25; IBM, Chicago, IL, USA).

Results

Most women (89.1%) reported never-use of tobacco products during pregnancy, while 150 (6.5%) reported snus only and 102 (4.4%) reported cigarette smoking, including 15 (0.6%) dual users. Up to 18 weeks of pregnancy 138 (6.0%) women used snus only at some time or current, and 12 (0.6%) up to 34 weeks. The majority (>90%) of the snus and smoking/dual-using women stopped within pregnancy week six. Exposure to nicotine products was similar in term and preterm infants, as described in detail in the supplementary material and table S2.

The exposure groups never, snus only and smoke/dual differed significantly from each other with respect to gestational age at birth, maternal age, maternal gestational weight gain, parity and socioeconomic factors, as listed in table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Background characteristics of the study population (n=2313) stratified by tobacco exposure during pregnancy

Unadjusted analyses showed no significant difference in birthweight among the women who used snus only compared to never and smoke/dual users (table 2). We observed significantly higher birthweight in infants exposed to snus only up to 18 weeks (table 3) after adjusting for parity, gestational age at birth, fetal sex, pre-pregnancy BMI and maternal age in multivariable regression analyses. However, after adjusting for maternal gestational weight gain (from pre-pregnancy to gestational week 18), the associations were no longer statistically significant in sensitivity analyses (table 3). We found no significant interaction between gestational weight gain and the tobacco exposure groups.

View this table:
  • View inline
  • View popup
TABLE 2

Anthropometric measures and proportional size are given by tobacco exposure groups for 2313 newborn infants

View this table:
  • View inline
  • View popup
TABLE 3

Linear regression analyses: effect of tobacco exposure during pregnancy on birthweight (grams)

For the “snus up to 34 weeks” group, there was a nonsignificant trend of decreased birthweight.

The only other anthropometric measure with significant associations to snus exposure in unadjusted (table 2) and adjusted regression analyses (supplementary table S4) was head circumference. However, after adjusting for maternal gestational weight gain (from pre-pregnancy to gestational week 18) in sensitivity analyses, the association was no longer significant. We found no other significant associations between snus exposure in the univariable or multivariable regression analyses on anthropometric (supplementary table S4) or proportional size outcomes (supplementary table S5).

Discussion

In our cohort, in which 90% of the women stopped snus use at recognised pregnancy, snus exposure was not significantly associated with birthweight or other anthropometric or proportional size measures.

To our knowledge, this is the first prospective mother–child cohort study showing that the use of snus in pregnancy was not associated with infant birth size. Our results are supported by registry studies showing that women who quit snus early in pregnancy had the same risk of SGA or low birthweight of the baby as non-snus users [28, 32]. This is in contrast to an Indian cohort study of 1217 women interviewed during months 3–7 of pregnancy at house-to-house visits showing an average of 105 g lower birthweight among the 17% reporting daily use of chewable tobacco for ≥6 months [27]. However, there are important differences between the studies in regards to types of smokeless tobacco products, prevalence of exposures as well as probable cultural and sociodemographic differences. In view of the presumably low total in utero nicotine exposure in our study, with most women stopping in early pregnancy, our findings are in line with other studies showing that early cessation attenuates the effects of snus [32] or smoking [7].

The apparently higher birthweight in infants born to mothers using snus up to 18 weeks of pregnancy only, before adjusting for maternal weight gain, is in contrast to registry studies from Sweden, where nonsignificant reductions in birthweight were observed in sibling analyses [28]. However, sensitivity analyses showed that the significantly higher maternal gestational weight gain in those stopping snus use compared to non-users largely explained the difference in the model not adjusting for weight gain. We are unaware of studies including maternal gestational weight gain in their adjusted models, but propose that maternal gestational weight gain should be included in analyses exploring potential effects of nicotine exposure in utero on fetal growth. This is supported by studies showing an increased risk of excess gestational weight gain from pre-pregnancy to delivery when quitting smoking in pregnancy compared to non-smokers [30, 31] and substantially lower rate of neonatal birthweight below the 10th percentile [33]. However, we are unaware of studies on maternal gestational weight gain after snus cessation during pregnancy.

We were unable to conclude on the effects of continuous snus exposure through pregnancy up to 34 weeks, with only 11 subjects in this exposure group. Thus, the potential effect of continued use of snus throughout pregnancy is still uncertain. We did see a nonsignificant trend of decreased birthweight in this group, which is in line with the Indian study of smokeless tobacco [27], as well as in conventional [32], but not in sibling analyses in the Swedish birth registry study [26].

To our knowledge, this is the first study to investigate the potential effect of snus exposure in pregnancy on anthropometric and proportional size measures at birth. Birth size is determined by genetic predisposition and by the intrauterine environment, including potential unfavourable in utero exposures affecting fetal growth [34]. While birthweight and length are predictors of lean mass [35], abdominal circumference may indicate level of fat and/or size of the liver [34], and upper mid arm circumference predicts muscle mass [36]. Our study with predominantly early transient exposure to snus was not able to replicate the adverse effects on differential fetal growth by exposure to cigarette smoke [2, 3, 10].

The study is strengthened by the prospective design, specifically designed questionnaires completed at 18 and 34 weeks of pregnancy with detailed information on the use of products containing nicotine during pregnancy and time of cessation specified by 2-week intervals. The study provides standardised detailed anthropometric measurements conducted by trained study personnel within the first 24 h after delivery.

The high early pregnancy cessation rates of both snus use and cigarette smoking in this study is clearly positive for maternal and infant health, but limited our ability to study the effects of persistent use during pregnancy. Nevertheless, it provides important information for pregnant women who have stopped using snus or are planning to quit, as well as for health professionals providing their prenatal care, that early exposure does not seem to affect the birth size of the baby. In addition, detailed information of frequency of use and number of snus portions and/or cigarettes smoked among those who stopped when recognising their pregnancies are lacking, thus limiting the possibilities to assess dose–response effects. Our data are based on self-reports with no objective validation of nicotine or cotinine levels during pregnancy. Nevertheless, studies have shown that self-reports represent valid markers for tobacco exposure [37, 38]. There is uncertainty regarding the exact pregnancy week of self-reported cessation, as we do not know if the subjects reported the ultrasound corrected gestational age or the calculated gestational age from the last menstrual period. If the reported gestational age was the latter, the first two pregnancy weeks correspond with the last 2 weeks before conception, thus nicotine exposure to the offspring might be limited. The gestational age was determined based upon the routine ultrasound examination, as described in the supplementary material, with a potential variation that could not be accounted for in the present analyses. Additionally, we only adjust for weight gain in the first 18 weeks of pregnancy, since we do not have weight of the mothers at delivery. However, since most women stopped using snus by pregnancy week six, one might assume the weight gain effect related to cessation might be in the period up to 18 weeks of pregnancy. Although the participants were recruited from a nonselected general population, the educational level in our study was higher than in the Norwegian general population [29]. However, this is unlikely to impact the prevalence of snus use, since we have recently found that educational level is not associated with snus use during pregnancy [16]. It might affect the choice of lifestyle and diet, potentially influencing fetal growth. As this is a prospective cohort study, nonparticipation cannot be associated with the outcome. Therefore, effect estimates of snus use on birth outcomes should not be biased [39]. Potential covariates such as pre-eclampsia, gestational diabetes or other relevant maternal diseases that possibly could explain birth size were unavailable at the time of analyses.

Conclusion

Maternal snus use in pregnancy, with most subjects stopping when knowing about their pregnancy, was not significantly associated with birthweight or anthropometric or proportional size measures of the newborn infants. Due to low prevalence of snus users up to 34 weeks of gestation, we could not conclude on potential effects of continued snus exposure in pregnancy on infant birth size.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material 00255-2019.SUPPLEMENT

Acknowledgements

PreventADALL study group: Anna Asarnoj (Astrid Lindgren Children's Hospital, Karolinska University Hospital, and Dept of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden), Oda C. Lødrup Carlsen (Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway), Åshild Wik Despriée (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, the Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, and VID Specialized University, Oslo, Norway), Kim A. Endre (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, the Division of Paediatrics and Adolescent Medicine, and Dept of Dermatology, Oslo University Hospital, Oslo, Norway), Peder A. Granlund (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, and the Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway), Hrefna K. Gudmundsdóttir (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, and the Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway), Henrik Holmstrøm (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, and the Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway), Geir Håland (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, and the Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway), Caroline-Aleksi O. Mägi (Astrid Lindgren Children's Hospital, Karolinska University Hospital, and Dept of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden), Unni C. Nygaard (Dept of Toxicology and Risk Assessment, Norwegian Institute of Public Health, Oslo, Norway), Eva Maria Rehbinder (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, the Division of Paediatrics and Adolescent Medicine, and Dept of Dermatology, Oslo University Hospital, Oslo, Norway), Knut Rudi (Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway), Carina M. Saunders (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, and Division of Paediatrics and Adolescent Medicine, Oslo University Hospital, Oslo, Norway), Ingebjørg Skrindo (Dept of Ear, Nose and Throat, Akershus University Hospital, Lørenskog, Norway), Cilla Söderhäll (Astrid Lindgren Children's Hospital, Karolinska University Hospital, and Dept of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden), Sandra G. Tedner (Astrid Lindgren Children's Hospital, Karolinska University Hospital, and Dept of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden), Magdalena R. Værnesbranden (Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, and Dept of Obstetrics and Gynaecology, Østfold Hospital Trust, Kalnes, Norway) and Johanna Wiik (Dept of Obstetrics and Gynaecology, Østfold Hospital Trust, Kalnes, Norway, and Dept of Obstetrics and Gynaecology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden).

The study was performed within the ORAACLE group (the Oslo Research Group of Asthma and Allergy in Childhood; the Lung and Environment). We sincerely thank all the study participants and the individuals involved in facilitating and running the study, especially Ann Berglind, Malén Gudbrandsgard, Mari Rønning Kjendsli, Natasha Sedergren, Päivi Söderman and Ellen Tegnerud.

Footnotes

  • Author contributions: All authors have contributed substantially to the design and/or clinical follow-up of the PreventADALL study, and have revised the work critically for important intellectual content and approved the final version before submission.

  • This article has supplementary material available from openres.ersjournals.com

  • This study is registered at www.clincialtrials.gov with identifier number NCT02449850.

  • Support statement: The study was funded by the Regional Health Board South East, the Norwegian Research Council, Oslo University Hospital, the University of Oslo, Health and Rehabilitation Norway, and Østfold Hospital Trust; by unrestricted grants from the Norwegian Association of Asthma and Allergy, the Kloster Foundation, the Norwegian Society of Dermatology and Venerology, Arne Ingel's Legat, Fürst Medical Laboratory, the Foundation for Healthcare and Allergy Research in Sweden (Vårdalstiftelsen), Swedish Asthma and Allergy Association's Research Foundation, the Swedish Research Council Initiative for Clinical Therapy Research, the Swedish Heart–Lung Foundation, SFO-V Karolinska Institutet, and the Hesselman Research Foundation; and Thermo Fisher (Uppsala, Sweden) by supplying allergen reagents. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: I. Kreyberg has nothing to disclose.

  • Conflict of interest: K. Hilde has nothing to disclose.

  • Conflict of interest: K.E.S. Bains has nothing to disclose.

  • Conflict of interest: K-H. Carlsen has nothing to disclose.

  • Conflict of interest: B. Granum has nothing to disclose.

  • Conflict of interest: G. Haugen has nothing to disclose.

  • Conflict of interest: G. Hedlin has nothing to disclose.

  • Conflict of interest: C.M. Jonassen has nothing to disclose.

  • Conflict of interest: L.S. Nordhagen has nothing to disclose.

  • Conflict of interest: B. Nordlund has nothing to disclose.

  • Conflict of interest: C.S. Rueegg has nothing to disclose.

  • Conflict of interest: K.D. Sjøborg has nothing to disclose.

  • Conflict of interest: H.O. Skjerven has nothing to disclose.

  • Conflict of interest: A.C. Staff has nothing to disclose.

  • Conflict of interest: R. Vettukattil has nothing to disclose.

  • Conflict of interest: K.C. Lødrup Carlsen has received grants as declared in the support statement and an honorarium from Thermo Fisher Scientific for a lecture given at the 2018 EAACI conference.

  • Received September 18, 2019.
  • Accepted October 7, 2019.
  • Copyright ©ERS 2019
http://creativecommons.org/licenses/by-nc/4.0/

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. 2014, Atlanta, Centers for Disease Control and Prevention (US).
  2. ↵
    1. Inoue S,
    2. Naruse H,
    3. Yorifuji T, et al.
    Impact of maternal and paternal smoking on birth outcomes. J Public Health 2017; 39: 1–10. doi:10.1093/pubmed/fdw050
    OpenUrl
  3. ↵
    1. Kharkova OA,
    2. Grjibovski AM,
    3. Krettek A, et al.
    Effect of smoking behavior before and during pregnancy on selected birth outcomes among singleton full-term pregnancy: a Murmansk County birth registry study. Int J Environ Res Public Health 2017; 14: E867. doi:10.3390/ijerph14080867
    OpenUrl
  4. ↵
    1. Voigt M,
    2. Briese V,
    3. Jorch G, et al.
    The influence of smoking during pregnancy on fetal growth. Considering daily cigarette consumption and the SGA rate according to length of gestation. Z Geburtshilfe Neonatol 2009; 213: 194–200. doi:10.1055/s-0029-1214405
    OpenUrlCrossRefPubMed
    1. Kvalvik LG,
    2. Haug K,
    3. Klungsøyr K, et al.
    Maternal smoking status in successive pregnancies and risk of having a small for gestational age infant. Paediatr Perinat Epidemiol 2017; 31: 21–28. doi:10.1111/ppe.12333
    OpenUrl
  5. ↵
    1. Pereira PP,
    2. Da Mata FA,
    3. Figueiredo AC, et al.
    Maternal active smoking during pregnancy and low birthweight in the Americas: a systematic review and meta-analysis. Nicotine Tob Res 2017; 19: 497–505. doi:10.1093/ntr/ntw228
    OpenUrl
  6. ↵
    1. England LJ,
    2. Kendrick JS,
    3. Gargiullo PM, et al.
    Measures of maternal tobacco exposure and infant birth weight at term. Am J Epidemiol; 153: 954–960. doi:10.1093/aje/153.10.954
  7. ↵
    1. Berlin I,
    2. Golmard JL,
    3. Jacob N, et al.
    Cigarette smoking during pregnancy: do complete abstinence and low level cigarette smoking have similar impact on birth weight? Nicotine Tob Res 2017; 19: 518–524. doi:10.1093/ntr/ntx033
    OpenUrl
  8. ↵
    1. Abraham M,
    2. Alramadhan S,
    3. Iniguez C, et al.
    A systematic review of maternal smoking during pregnancy and fetal measurements with meta-analysis. PLoS One 2017; 12: e0170946. doi:10.1371/journal.pone.0170946
    OpenUrl
  9. ↵
    1. Bernstein IM,
    2. Plociennik K,
    3. Stahle S, et al.
    Impact of maternal cigarette smoking on fetal growth and body composition. Am J Obstet Gynecol 2000; 183: 883–886. doi:10.1067/mob.2000.109103
    OpenUrlCrossRefPubMed
  10. ↵
    1. Jamal A,
    2. Gentzke A,
    3. Hu SS, et al.
    Tobacco use among middle and high school students – United States, 2011–2016. MMWR Morb Mortal Wkly Rep 2017; 66: 597–603. doi:10.15585/mmwr.mm6623a1
    OpenUrlPubMed
  11. ↵
    Statistics Norway. Snus More Used than Cigarettes. www.ssb.no/en/helse/artikler-og-publikasjoner/snus-more-used-than-cigarettes. Date last updated: January 18, 2018.
  12. ↵
    1. Lange S,
    2. Probst C,
    3. Rehm J, et al.
    National, regional, and global prevalence of smoking during pregnancy in the general population: a systematic review and meta-analysis. Lancet Glob Health 2018; 6: e769–e776. doi:10.1016/S2214-109X(18)30223-7
    OpenUrl
  13. ↵
    The National Board of Health and Welfare. Statistics on Pregnancies, Deliveries and Newborn Infants 2016. 2018. www.socialstyrelsen.se/statistik-och-data/statistik/statistikamnen/graviditeter-forlossningar-och-nyfodda
  14. ↵
    1. Rygh E,
    2. Gallefoss F,
    3. Reiso H
    . Use of snus and smoking tobacco among pregnant women in the Agder counties. Tidsskr Nor Laegeforen 2016; 136: 1351–1354. doi:10.4045/tidsskr.15.1341
    OpenUrl
  15. ↵
    1. Kreyberg I,
    2. Bains KES,
    3. Carlsen KH, et al.
    Stopping when knowing: use of snus and nicotine during pregnancy in Scandinavia. ERJ Open Res 2019; 5: 00197-2018. doi:10.1183/23120541.00197-2018
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Lambers DS,
    2. Clark KE
    . The maternal and fetal physiologic effects of nicotine. Semin Perinatol 1996; 20: 115–126. doi:10.1016/S0146-0005(96)80079-6
    OpenUrlCrossRefPubMed
  17. ↵
    1. Köhler E,
    2. Avenarius S,
    3. Rabsilber A, et al.
    Nicotine and its metabolites in amniotic fluid at birth – assessment of prenatal tobacco smoke exposure. Hum Exp Toxicol 2010; 29: 385–391. doi:10.1177/0960327110363326
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kreyberg I,
    2. Nordhagen LS,
    3. Bains KES, et al.
    An update on prevalence and risk of snus and nicotine replacement therapy during pregnancy and breastfeeding. Acta Paediatr 2019 108: 1215– 1221. doi:10.1111/apa.14737
    OpenUrl
  19. ↵
    1. Spindel ER,
    2. McEvoy CT
    . The role of nicotine in the effects of maternal smoking during pregnancy on lung development and childhood respiratory disease. Implications for dangers of E-cigarettes. Am J Respir Crit Care Med 2016; 193: 486–494. doi:10.1164/rccm.201510-2013PP
    OpenUrlCrossRefPubMed
  20. ↵
    1. Baba S,
    2. Wikström AK,
    3. Stephansson O, et al.
    Influence of smoking and snuff cessation on risk of preterm birth. Eur J Epidemiol 2012; 27: 297–304. doi:10.1007/s10654-012-9676-8
    OpenUrlCrossRefPubMed
  21. ↵
    1. Baba S,
    2. Wikström AK,
    3. Stephansson O, et al.
    Influence of snuff and smoking habits in early pregnancy on risks for stillbirth and early neonatal mortality. Nicotine Tob Res 2014; 16: 78–83. doi:10.1093/ntr/ntt117
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wikström AK,
    2. Cnattingius S,
    3. Stephansson O
    . Maternal use of Swedish snuff (snus) and risk of stillbirth. Epidemiology 2010; 21: 772–778. doi:10.1097/EDE.0b013e3181f20d7e
    OpenUrlCrossRefPubMed
  23. ↵
    1. Gunnerbeck A,
    2. Edstedt Bonamy AK,
    3. Wikström AK, et al.
    Maternal snuff use and smoking and the risk of oral cleft malformations – a population-based cohort study. PLoS One 2014; 9: e84715. doi:10.1371/journal.pone.0084715
    OpenUrlCrossRefPubMed
  24. ↵
    1. Gunnerbeck A,
    2. Wikström AK,
    3. Bonamy AK, et al.
    Relationship of maternal snuff use and cigarette smoking with neonatal apnea. Pediatrics 2011; 128: 503–509. doi:10.1542/peds.2010-3811
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Nordenstam F,
    2. Lundell B,
    3. Cohen G, et al.
    Prenatal exposure to snus alters heart rate variability in the infant. Nicotine Tob Res 2017; 19: 797–803. doi:10.1093/ntr/ntx035
    OpenUrl
  26. ↵
    1. Gupta PC,
    2. Subramoney S,
    3. Sreevidya S
    . Smokeless tobacco use, birthweight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India. BMJ 2004; 328: 1538. doi:10.1136/bmj.38113.687882.EB
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Juárez SP,
    2. Merlo J
    . The effect of Swedish snuff (snus) on offspring birthweight: a sibling analysis. PLoS One 2013; 8: e65611. doi:10.1371/journal.pone.0065611
    OpenUrl
  28. ↵
    1. Lødrup Carlsen KC,
    2. Rehbinder EM,
    3. Skerjven HO, et al.
    Preventing Atopic Dermatitis and ALLergies in Children – the PreventADALL study. Allergy 2018; 73: 2063–2070.
    OpenUrl
  29. ↵
    1. Favaretto AL,
    2. Duncan BB,
    3. Mengue SS, et al.
    Prenatal weight gain following smoking cessation. Eur J Obstet Gynecol Reprod Biol 2007; 135: 149–153. doi:10.1016/j.ejogrb.2006.11.014
    OpenUrlCrossRefPubMed
  30. ↵
    1. Adegboye AR,
    2. Rossner S,
    3. Neovius M, et al.
    Relationships between prenatal smoking cessation, gestational weight gain and maternal lifestyle characteristics. Women Birth 2010; 23: 29–35. doi:10.1016/j.wombi.2009.05.002
    OpenUrlCrossRefPubMed
  31. ↵
    1. Baba S,
    2. Wikström AK,
    3. Stephansson O, et al.
    Changes in snuff and smoking habits in Swedish pregnant women and risk for small for gestational age births. BJOG 2013; 120: 456–462. doi:10.1111/1471-0528.12067
    OpenUrlCrossRefPubMed
  32. ↵
    1. Rode L,
    2. Kjærgaard H,
    3. Damm P, et al.
    Effect of smoking cessation on gestational and postpartum weight gain and neonatal birthweight. Obstet Gynecol 2013; 122: 618–625. doi:10.1097/AOG.0b013e3182a10836
    OpenUrlCrossRefPubMed
  33. ↵
    1. Barker DJ
    . The fetal and infant origins of disease. Eur J Clin Invest 1995; 25: 457–463. doi:10.1111/j.1365-2362.1995.tb01730.x
    OpenUrlCrossRefPubMed
  34. ↵
    1. Koo WW,
    2. Walters JC,
    3. Hockman EM
    . Body composition in human infants at birth and postnatally. J Nutr 2000; 130: 2188–2194. doi:10.1093/jn/130.9.2188
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. D'Angelo S,
    2. Yajnik CS,
    3. Kumaran K, et al.
    Body size and body composition: a comparison of children in India and the UK through infancy and early childhood. J Epidemiol Community Health 2015; 69: 1147–1153. doi:10.1136/jech-2014-204998
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. George L,
    2. Granath F,
    3. Johansson AL, et al.
    Self-reported nicotine exposure and plasma levels of cotinine in early and late pregnancy. Acta Obstet Gynecol Scand 2006; 85: 1331–1337. doi:10.1080/00016340600935433
    OpenUrlCrossRefPubMed
  37. ↵
    1. Kvalvik LG,
    2. Nilsen RM,
    3. Skjærven R, et al.
    Self-reported smoking status and plasma cotinine concentrations among pregnant women in the Norwegian Mother and Child Cohort Study. Pediatr Res 2012; 72: 101–107. doi:10.1038/pr.2012.36
    OpenUrlCrossRefPubMed
  38. ↵
    1. Rothman KJ
    . Epidemiology – An Introduction. New York, Oxford University Press, 2002.
PreviousNext
Back to top
Vol 5 Issue 4 Table of Contents
ERJ Open Research: 5 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Snus in pregnancy and infant birth size: a mother–child birth cohort study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Snus in pregnancy and infant birth size: a mother–child birth cohort study
Ina Kreyberg, Katarina Hilde, Karen Eline S. Bains, Kai-Håkon Carlsen, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Christine M. Jonassen, Live S. Nordhagen, Björn Nordlund, Corina S. Rueegg, Katrine D. Sjøborg, Håvard O. Skjerven, Anne C. Staff, Riyas Vettukattil, Karin C. Lødrup Carlsen, the PreventADALL Study Group
ERJ Open Research Oct 2019, 5 (4) 00255-2019; DOI: 10.1183/23120541.00255-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Snus in pregnancy and infant birth size: a mother–child birth cohort study
Ina Kreyberg, Katarina Hilde, Karen Eline S. Bains, Kai-Håkon Carlsen, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Christine M. Jonassen, Live S. Nordhagen, Björn Nordlund, Corina S. Rueegg, Katrine D. Sjøborg, Håvard O. Skjerven, Anne C. Staff, Riyas Vettukattil, Karin C. Lødrup Carlsen, the PreventADALL Study Group
ERJ Open Research Oct 2019, 5 (4) 00255-2019; DOI: 10.1183/23120541.00255-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Subjects and methods
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Paediatric pulmonology
  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The burden of caring for people with severe asthma
  • Nicotine upregulates ACE2 expression
  • Randomised trial of Mycobacterium w in COVID-19
Show more Original articles

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2021 by the European Respiratory Society